Vault-13

NKGEN BIOTECH INC NKGN

COM · Common Stock · CUSIP 65488A101

1 institutional holders +0 vs Q1 2026
2,755,9352.8m shares reported held*
$165.4kreported value*
0 new 0 added 0 reduced 0 sold out net bought ≈ $0

* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $0.06.

Trends to Q2 2026

Institutional holders

Managers reporting a position, each quarter

0102030Q4 23: 10Q1 24: 14Q2 24: 18Q3 24: 20Q4 24: 26Q1 25: 3Q2 25: 0Q3 25: 1Q4 25: 1Q1 26: 1Q2 26: 11Q4 23Q2 24Q4 24Q2 25Q4 25Q2 26
Numbers
QuarterHolders
Q4 202310
Q1 202414
Q2 202418
Q3 202420
Q4 202426
Q1 20253
Q2 20250
Q3 20251
Q4 20251
Q1 20261
Q2 20261

Buyers vs sellers

Managers adding to or starting a position, vs cutting or selling out

Bought or addedCut or sold out
40040Q3 24: 10 bought or addedQ3 24: 4 cut or sold outQ4 24: 11 bought or addedQ4 24: 9 cut or sold outQ4 24Q1 25: 1 bought or addedQ1 25: 25 cut or sold outQ2 25: 0 bought or addedQ2 25: 3 cut or sold outQ2 25Q3 25: 1 bought or addedQ3 25: 0 cut or sold outQ4 25: 0 bought or addedQ4 25: 0 cut or sold outQ4 25Q1 26: 0 bought or addedQ1 26: 0 cut or sold outQ2 26: 0 bought or addedQ2 26: 0 cut or sold outQ2 26
Numbers
QuarterBought or addedCut or sold out
Q3 2024104
Q4 2024119
Q1 2025125
Q2 202503
Q3 202510
Q4 202500
Q1 202600
Q2 202600

Major shareholders (over 5%)

Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.

HolderStakeChangeShares Last filed
Song Paul Y. 13D · may seek influence new · filed 2025-05-12
Stated purposeThe securities were acquired for investment purposes and to align with the strategic direction of the Company. The Reporting Person, as President and CEO of NKGen Biotech, Inc., currently exercises influence over management, operations, and corporate policy. Except as described herein, the Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions enumerated in this Item 4, although the Reporting Person reserves the right to formulate such plans or proposals in the future. Full filing
 54.3% new 63.7m 2025-05-12
CFIC-2015 NV Family Investments, LLC 13D · may seek influence new · filed 2025-06-02
Stated purposeThe securities were acquired for investment purposes. From time to time, the Reporting Persons and their affiliates may engage in discussions with management, the board of directors (the "Board"), and stockholders of the Issuer and other relevant parties regarding business practices and governance policies of the Company. The Reporting Persons intend to monitor the performance and corporate governance of the Company, as well as the actions of the Company's management and Board and will assert stockholder rights as deemed necessary. Other than as described in this paragraph, the Reporting Persons have no present plans or proposals that relate to or would result in any of the actions enumerated in Item 4 of Schedule 13D. Full filing
 47.2% new 63.2m 2025-06-02
PATHSTONE FAMILY OFFICE, LLC 13G · institution new · filed 2025-02-28 7.9% new 2.8m 2025-02-28
METEORA CAPITAL, LLC 13G · institution -1.7 pts · filed 2025-05-15 6.1% -1.7 pts 2.8m 2025-05-15

Holders, Q2 2026

#ManagerLocationShares Value% of their portfolioChangeShares change
1 Meteora Capital, LLC 0.01% of their portfolio Boca Raton, FL 2,755,9352.8m $165.4k $165.4k 0.01% Unchanged